Several statins increase body and liver fat accumulation in a model of metabolic syndrome

Journal of Physiology and Pharmacology

Volumn 64, Issue 3, 2013, Pages

  Aguirre, Leixuri ^a,b   Hijona, E ^c   Macarulla, M T ^a,b   Gracia, A ^a,b   Larrechi, I ^a   Bujanda, L ^c   Hijona, L ^c   Portillo, M P ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

Author keywords

Adipose tissue; Body fat; Fatty acid oxidation; Lipogenesis; Lipoprotein lipase; Liver fat; Metabolic syndrome; Statins; Zucker rat

Indexed keywords

ACYL COENZYME A OXIDASE; ATORVASTATIN; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE IA; FATTY ACID SYNTHASE; FLUINDOSTATIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; MALATE DEHYDROGENASE (DECARBOXYLATING); MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FOOD INTAKE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID STORAGE; LIVER HISTOLOGY; LIVER INJURY; LIVER WEIGHT; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PROTEIN EXPRESSION; RAT; SUBCUTANEOUS FAT; WEIGHT CHANGE; WHITE ADIPOSE TISSUE; ABDOMINAL SUBCUTANEOUS FAT; ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; FATTY LIVER; HYPERCHOLESTEROLEMIA; LIPOGENESIS; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; ZUCKER RAT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT;

ADIPOSITY; ANIMALS; DISEASE MODELS, ANIMAL; FATTY ACID SYNTHASE, TYPE I; FATTY LIVER; GLUCOSEPHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPOGENESIS; LIPOPROTEIN LIPASE; LIVER; MALE; METABOLIC SYNDROME X; RANDOM ALLOCATION; RATS; RATS, ZUCKER; SUBCUTANEOUS FAT, ABDOMINAL; TRIGLYCERIDES;

EID: 84881580030     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. The Cochrane Library 2011; Issue 8. http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/StatinsUpdate-FINAL.pdf
2. Saito Y. Pitavastatin: an overview. Atherosclerosis Suppl 2011; 12: 271-276.
3. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99: 95-112.
4. Tzefos M, Olin JL. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. J Clin Lipidol 2011; 5: 450-459.
5. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41: 690-695.
6. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8: 373-418.
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
8. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
9. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
10. Official Methods of Analysis (13th ed.). Association of Official Analytical Chemists, Washington, DC, 1980.
11. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatosis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
12. Zabala A, Churruca I, Macarulla MT, et al. The trans-10, cis-12 isomer of conjugated linoleic acid reduces hepatic triacylglycerol content without affecting lipogenic enzymes in hamsters. Br J Nutr 2004; 92: 383-389.
13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
14. Del Prado M, Hernandez-Montes H, Villalpando S. Characterization of a fluorometric method for lipoprotein lipase. Arch Med Res 1994; 25: 331-335.
15. Miranda J, Churruca I, Fernandez-Quintela A, et al. Weak effect of trans-10, cis-12-conjugated linoleic acid on body fat accumulation in adult hamsters. Br J Nutr 2009; 102: 1583-1589.
16. Alberdi G, Rodriguez VM, Macarulla MT, et al. Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition 2013; 29: 562-567
17. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol 2011; 26: 342-347.
18. Sattar N, Taskinen MR. Statins are diabetogenic-myth or reality? Atherosclerosis Suppl 2012; 13: 1-10.
19. Goldstein MR, Mascitelli L. Do statins cause diabetes? Curr Diab Rep 2013; 13: 381-390.
20. Argiles JM. The obese Zucker rat: a choice for fat metabolism. Prog Lipid Res 1989; 28: 33-66.
21. Parikh NI, Keyes MJ, Larson MG, Pou KM. Visceral and subcutaneous adiposity and brachial artery vasodilator function. Obesity 2009; 17: 2054-2059.
22. Rodriguez A, Catalan V, Gomez-Ambrosi J, Fruhbeck G. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 2007; 13: 2169-2175.
23. Fierbinteteanu-Braticevici C, Negreanu L, Tarantino G. Is fatty liver always benign and should not consequently be treated? J Physiol Pharmacol 2013; 64: 3-9.
24. Salem NA, Assaf N, Ahmed HH. Pleiotropic effects of rimonabant and simvastatin on obesity associated multiple metabolic risk factors in rats. Eur Rev Med Pharmacol Sci 2012; 16: 797-807.
25. Erol A. The role of fat tissue in the cholesterol lowering and the pleiotropic effects of statins-statins activate the generation of metabolically more capable adipocytes. Med Hypotheses 2005; 64: 69-73.
26. Bey L, Maigret P, Laouenan H, Hamilton MT. Induction of lipoprotein lipase gene expression in 3T3-L1 preadipocytes by atorvastatin, a cholesterol-and triglyceride-lowering drug. Pharmacology 2002; 66: 51-56.
27. Sandhya VG, Rajamohan T. Comparative evaluation of the hypolipidemic effects of coconut water and lovastatin in rats fed fat-cholesterol enriched diet. Food Chem Toxicol 2008; 46: 3586-3592.
28. Rodriguez-Calvo R, Barroso E, Serrano L, et al. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology 2009; 49: 106-115.
29. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res 2001; 40: 439-452.
30. Katsurada A, Iritani N, Fukuda H, et al. Effects of nutrients and hormones on transcriptional and post-transcriptional regulation of fatty acid synthase in rat liver. Eur J Biochem 1999; 190: 427-433.
31. Kim K, Park S, Kim Y. Regulation of fatty acid synthase at transcriptional and post-transcriptional levels in rat liver. Yonsei Med J 1992; 33: 199-208.
32. Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann NY Acad Sci 2013; 128: 106-122.
33. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005; 330: 326-335.
34. Grigorescu M, Crisan D, Radu C, Grigorescu MD, Sparchez Z, Serban A. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis. J Physiol Pharmacol 2012; 63: 347-353.
35. Ohmura C, Watada H, Hirose T, Tanaka Y, Kawamori R. Acute onset and worsening of diabetes concurrent with administration of statins. Endocr J 2005; 52: 369-372.
36. Lalli CA, Pauli JR, Prada PO, et al., Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet. Metabolism 2008; 57: 57-65.
37. Szendroedi J, Anderwald C, Krssak M, et al. Effects of high dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009; 32: 209-214.
38. Krysiak R, Okopien B. Different effects of simvastatin on ex vivo monocyte cytokine release in patients with hypercholesterolemia and impaired glucose tolerance. J Physiol Pharmacol 2010; 61: 725-732.